"NeoSep1 is a pioneering clinical trial that aims to identify effective and safe antibiotic combinations to treat sepsis in newborns. One of the centres leading the second phase of this study is the Kemri-Wellcome Trust Research Programme (KWTRP) in Kilifi. Newborn babies are particularly vulnerable to sepsis, a life-threatening infection, because their underdeveloped immune systems struggle to fight off pathogens. Each year, neonatal sepsis is responsible for an estimated 800,000 deaths worldwide, while in Africa it accounts for 28% of all neonatal deaths."
"GARDP study in 2023 revealed that more than 200 different antibiotic combinations are being used to treat neonatal sepsis around the world. Sally Ellis, project leader of the children's antibiotics programme at GARDP, says this variety of antibiotics encourages bacteria to become resistant. At an early stage of the project, NeoSep1 research teams confirmed the correct dosages for three new co"
NeoSep1 is a clinical trial testing effective, safe combinations of existing antibiotics to treat neonatal sepsis and curb antimicrobial resistance. Kemri-Wellcome Trust Research Programme (KWTRP) in Kilifi leads phase two of the trial. Neonatal sepsis causes about 800,000 deaths annually worldwide and 28% of neonatal deaths in Africa; AMR causes up to 214,000 neonatal deaths globally. Over 200 different antibiotic combinations are currently used to treat neonatal sepsis worldwide, driving resistance. NeoSep1 compares new antibiotic combinations with current regimens and seeks to minimise unnecessary antibiotic exposure to reduce resistance.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]